Swalqol in Primary Hyperparathyroidism

June 1, 2021 updated by: Barış Sevinç, Uşak University

The Effect of Parathyroidectomy on Swallowing Related Quality of Life in Primary Hyperparathyroidism

Swallow related quality of life before and after parathyroidectomy will be evaluated in patients with primary hyperparathyridism.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients who will undergone parathyroidectomy for primary hyperparathyroidism will be included in the study. Swal-Qol and Sf-36 forms will be used for evaluation of quality of life before and 1 month after the surgery. The change in the quality of life and swallowing related quality of life will be evaluated.

Study Type

Observational

Enrollment (Actual)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Uşak, Turkey, 64100
        • Uşak University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients with primary hyperparathyroidism

Description

Inclusion Criteria:

  • no diagnosis of Alzheimers disease
  • must be able to swallow tablets Planned operation for primary hyperparathyroidism

Exclusion Criteria:

  • secondary or tertiary hyperparathyroidism
  • insulin dependent diabetes
  • thyroid disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
parathyroidectomy cases
patients who will be operated for primary hyperparathyroidism
routine parathyroidectomy will be done for the treatment of adenoma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in quality of life
Time Frame: 6 months
Quality of life will be evaluated using short form 36
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Barış Sevinç, Uşak University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 1, 2018

Primary Completion (ACTUAL)

July 1, 2020

Study Completion (ACTUAL)

November 1, 2020

Study Registration Dates

First Submitted

March 20, 2019

First Submitted That Met QC Criteria

May 27, 2019

First Posted (ACTUAL)

May 30, 2019

Study Record Updates

Last Update Posted (ACTUAL)

June 4, 2021

Last Update Submitted That Met QC Criteria

June 1, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • pthswalqol

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperparathyroidism

Clinical Trials on parathyroidectomy

3
Subscribe